HISTONDEACETYLASE HEMMER

BISARYLCARBINOL DERIVATIVES FOR INHIBITION LEUKOTRIENER BIO-SYNTHESIS

Inhibitors of histone deacetylase

Inhibitors of histone deacetylase

Inhibitors of histone deacetylase

Heteroarylnaphthalene hydroxy acids as inhibitors of leukotriene biosynthesis

METHODS, COMPOUNDS, COMPOSITIONS AND VEHICLES FOR DELIVERING 3-AMINO-1-PROPANESULFONIC ACID

The invention relates to methods, compounds, compositions and vehicles for delivering 3-amino-1 -propanesulfonic acid (3APS) in a subject, preferably a human subject. The invention encompasses compounds that will yield or generate 3APS, either in vitro or in vivo. Preferred compounds include amino acid prodrugs of 3APS for use, including but not limited to, the prevention and treatment of Alzheimer's disease.

THIOPYRANO (2,3,4-C,D) INDOLES AS INHIBITORS OF LEUKOTRIENE BIOSYNTHESIS

... 111/GL44 112/GL45 113/GL46 114/GL47 145/GL54 18311 TITLE OF THE INVENTIQN Thiopyrano¢2,3,4-c,d!indoles as Inhibitors of Leukotriene Biosynthesis Compounds having the formula I: I are inhibitors of leukotriene biosynthesis. These compounds are useful as anti-asthmatic, anti-allergic, anti-inflammatory, and cytoprotective agents. They are also useful in treating angina, cerebral spasm, glomerular nephritis, hepatitis, endotoxemia, psoriasis, uveitis and allograft rejection and in preventing the formation of atherosclerotic plaques.

INDENYL HYDROXAMIC ACIDS AND HYDROXY UREAS AS INHIBITORS OF 5-LIPOXYGENASE

Compounds having the formula I: (see formula I) are inhibitors of the 5-lipoxygenase enzyme. These compounds are useful as anti-asthmatic, anti-allergic, anti-inflammatory, and cytoprotective agents. They are also useful in treating diarrhea, hypertension, angina, platelet aggregation, cerebral spasm, premature labor, spontaneous abortion, dysmenorrhea, and migraine.

HETEROARYLNAPHTHALENE HYDROXY ACIDS AS INHIBITORS OF LEUKOTRIENE BIOSYNTHESIS

Compounds having formula (I) are inhibitors of leukotriene biosynthesis. These compounds are useful as anti-asthmatic, anti-allergic, anti-inflammatory, and cytoprotective agents. They are also useful in treating angina, cerebral spasm, glomerular nephritis, hepatitis, endotoxemia, uveitis, and allograft rejection and in preventing the formation of atherosclerotic plaques.

BISARYLCARBINOL DERIVATIVES AS INHIBITORS OF LEUKOTRIENE BIOSYNTHESIS

Compounds having the formula (I): R1R2C(OR3)-Ar1-X-Ar2-Ar3 are inhibitors of leukotriene biosynthesis. These compounds are useful as anti-asthmatic, antiallergic, anti-inflammatory, and cytoprotective agents. They are also useful in treating angina, cerebral spasm, glomerular nephritis, hepatitis, endotoxemia, uveitis, and allograft rejection and in preventing the formation of atherosclerotic plaques.

BISARYLCARBINOL-DERIVATE ZUR HEMMUNG LEUKOTRIENER-BIOSYNTHESE

BISARYLCARBINOL ZIMTSÄURE-DERIVATE ZUR HEMMUNG LEUKOTRIENER BIOSYNTHESE

6,8 DIOXABICYCLO[3.2.1]OCTANES AS INHIBITORS OF LEUKOTRIENE BIOSYNTHESIS

Compounds having the formula I: (see fig.I) are inhibitors of leukotriene biosynthesis. These compounds are useful as anti-asthmatic, antiallergic, anti-inflammatory, and cytoprotective agents. They are also useful in treating angina, cerebral spasm, glomerular nephritis, hepatitis, endotoxemia, uveitis and allograft rejection and in preventing the formation of atherosclerotic plaques.

1-(HYDROXYLAMINOALKYL) INDOLE DERIVATIVES AS INHIBITORS OF LEUKOTRIENE BIOSYNTHESIS

TITLE OF THE INVENTION 1-(HYDROXYLAMINOALKYL)INDOLE DERIVATIVES AS INHIBITORS OF LEUKOTRIENE BIOSYNTHESIS ABSTRACT Compounds having the formula I: I are inhibitors of leukotriene biosynthesis. These compounds are useful as anti-asthmatic, anti-aller-gic, anti-inflammatory, and cytoprotective agents. They are also useful in treating angina, cerebral spasm, glomerular nephritis, hepatitis, endotoxemiz, uveitis and allograft rejection and in preventing the formation of atherosclerotic plaques.

Inhibitors of histone deacetylase

The invention relates to the inhibition of histone deacetylase. The invention provides compounds and methods for inhibiting histone deacetylase enzymatic activity. The invention also provides compositions and methods for treating cell proliferative diseases and conditions.

Verfahren zum spezifischen Hemmen von Histon-Deacetylase-4

INHIBITORS FOR HISTONE DEACETYLASE ONES

Methods, compounds, compositions and vehicles for delivering 3-amino-1-propanesulfonic acid

ARYL THIOPYRANO(2,3,4-C,D)INDOLES AS INHIBITORS OF LEUKOTRIENE BIOSYNTHESIS

Compounds having formula (I) are inhibitors of 5-lipoxygenase and inhibitors of leukotriene biosynthesis. These compounds are useful as anti-asthmatic, anti-allergic, anti-inflammatory, and cytoprotective agents. They are also useful in treating angina, cerebral spasm, glomerular nephritis, hepatitis, endotoxemia, psoriasis, uveitis, and allograft rejection and in preventing the formation of atherosclerotic plaques.

HETEROARYLNAPHTHALENES AS INHIBITORS OF LEUKOTRIENE BIOSYNTHESIS

TITLE OF THE INVENTION HETEROARYLNAPHTHALENES AS INHIBITORS OF LEUKOTRIENE BIOSYNTHESIS Compounds having the formula I: are inhibitors of leukotriene biosynthesis. These compounds are useful as anti-asthmatic, antiallergic, anti-inflammatory, and cytoprotective agents. They are a1so useful in treating angina, cerebral spasm, glomerular nephritis, hepatitis, endotoxemia, uveitis and allograft rejection and in preventing the formation of atherosclerotic plaques.

HETEROARYLNAPHTHALENES AS INHIBITORS OF LEUKOTRIENE BIOSYNTHESIS

Compounds having the formula I: are inhibitors of leukotriene biosynthesis. These compounds are useful as anti-asthmatic, anti- allergic, anti-inflammatory, and cytoprotective agents. They are also useful in treating angina, cerebral spasm, glomerular nephritis, hepatitis, endotoxemia, uveitis and allograft rejection and in preventing the formation of atherosclerotic plaques.

INDENYL HYDROXAMIC ACIDS AND HYDROXY UREAS AS INHIBITORS OF 5-LIPOXYGENASE

Compounds having the formula I: (see formula I) are inhibitors of the 5-lipoxygenase enzyme. These compounds are useful as anti-asthmatic, anti-allergic, anti-inflammatory, and cytoprotective agents. They are also useful in treating diarrhea, hypertension, angina, platelet aggregation, cerebral spasm, premature labor, spontaneous abortion, dysmenorrhea, and migraine.

BISARYLCARBINOL CINNAMIC ACIDS AS INHIBITORS OF LEUKOTRIENE BIOSYNTHESIS

Compounds having the formula (I): R1R2C(OR3)-Ar1-X-Ar2-C(Ar3)=CHCO2H are inhibitors of leukotriene biosynthesis. These compounds are useful as anti-asthmatic, anti-allergic, anti-inflammatory, an d cytoprotective agents. They are also useful in treating angina, cerebral spasm, glomerular nephritis, hepatitis, endotoxemia, uveitis, and allograft rejection and in preventing the formation of atherosclerotic plaques.

BISARYLCARBINOL CINNAMIC ACIDS AS INHIBITORS OF LEUKOTRIENE BIOSYNTHESIS

Compounds having the formula (I): R1R2C(OR3)-Ar1-X-Ar2-C(Ar3)=CHCO2H are inhibitors of leukotriene biosynthesis. These compounds are useful as anti-asthmatic, anti-allergic, anti-inflammatory, and cytoprotective agents. They are also useful in treating angina, cerebral spasm, glomerular nephritis, hepatitis, endotoxemia, uveitis, and allograft rejection and in preventing the formation of atherosclerotic plaques.

INHIBITORS OF HISTONE DEACETYLASE

The invention relates to the inhibition of histone deacetylase. The invention provides compounds and methods for inhibiting histone deacetylase enzymatic activity. The invention also provides compositions and methods for treating cell proliferative diseases and conditions. © KIPO & WIPO 2007 ...

Inhibitors of histone deacetylase

The invention relates to the inhibition of histone deacetylase. The invention provides compounds and methods for inhibiting histone deacetylase enzymatic activity. The invention also provides compositions and methods for treating cell proliferative diseases and conditions.

Inhibitors of histone deacetylase

The invention relates to the inhibition of histone deacetylase. The invention provides compounds and methods for inhibiting histone deacetylase enzymatic activity. The invention also provides compositions and methods for treating cell proliferative diseases and conditions.

INHIBITOREN DER HISTON-DEACETYLASE

BISARYLCARBINOL ZIMTSÄURE DERIVATIVES FOR THE INHIBITION OF LEUKOTRIENER BIO-SYNTHESIS

SULFONAMIDOMETHYL PHOSPHONAT BETA LACTAMASE INHIBITORS

CONNECTIONS WITH ANALGETI EFFECT

INHIBITORS THE HISTON DEACETYLASE ONES

BISARYLCARBINOL DERIVATIVES AS INHIBITORS OF LEUKOTRIENE BIOSYNTHESIS

Compounds having the formula (I): R1R2C(OR3)-Ar1-X-Ar2-Ar3 are inhibitors of leukotriene biosynthesis. These compounds are useful as anti-asthmatic, anti-allergic, anti-inflammatory, and cytoprotecti ve agents. They are also useful in treating angina, cerebral spasm, glomerular nephritis, hepatitis, endotoxemia, uveitis, and allograft rejecti on and in preventing the formation of atherosclerotic plaques.

DIBENZOHETEROCYCLIC HYDROXAMIC ACIDS AND HYDROXY UREAS AS INHIBITORS OF 5-LIPOXYGENASE

Compounds having the formula I: (see formula I) are inhibitors of the 5-lipoxygenase enzyme. These compounds are useful as anti-asthmatic, anti-allergic, anti-inflammatory, and cytoprotective agents. They are also useful in treating diarrhea, hypertension, angina, platelet aggregation, cerebral spasm, premature labor, spontaneous abortion, dysmenorrhea, and migraine.

具有镇痛作用的新化合物

... 本申请公开并要求式(I)化合物、它们的药学上可接受的盐、含有这些新化合物的药用组合物以及它们在治疗中的用途，特别是在疼痛治疗中的用途。 ...

Inhibitors of histone deacetylase

Heteroarylnaphthalene lactones as inhibitors of leukotriene biosynthesis

HETEROARYLNAPHTHALENE LACTONES AS INHIBITORS OF LEUKOTRIENE BIOSYNTHESIS

Compounds having formula (I): are inhibitors of leukotriene biosynthesis. These compounds are useful as anti-asthmatic, anti-allergic, anti-inflammatory, and cytoprotective agents. They are also useful in treating angina, cerebral spasm, glomerular nephritis, hepatitis, endotoxemia, uveitis, and allograft rejection and in preventing the formation of atherosclerotic plaques.

INHIBITORS OF HISTONE DEACETYLASE

The invention relates to a series of compounds useful for inhibiting histone deacetylase (HDAC) enzymatic activity. The invention also provides a method for inhibiting histone descetylase in a cell using said compounds as well as a method for treating cell proliferative diseases and conditions using said HDAC inhibitors. Further, the invention provides pharmaceutical compositions comprising the HDAC inhibiting compounds and a pharmaceutically acceptable carrier. © KIPO & WIPO 2007 ...

BISARYLCARBINOL-DERIVATE ZUR HEMMUNG LEUKOTRIENER-BIOSYNTHESE

SULFONAMIDOMETHYL PHOSPHONAT BETA-LACTAMASE INHIBITOREN

Sulfonamidomethyl phosphonate inhibitors of beta-lactamase

Inhibitors of histone deacetylase

DIBENZOHETEROCYCLIC HYDROXAMIC ACIDS AND HYDROXY UREAS AS INHIBITORS OF 5-LIPOXYGENASE

Compounds having the formula I: (see formula I) are inhibitors of the 5-lipoxygenase enzyme. These compounds are useful as anti-asthmatic, anti-allergic, anti-inflammatory, and cytoprotective agents. They are also useful in treating diarrhea, hypertension, angina, platelet aggregation, cerebral spasm, premature labor, spontaneous abortion, dysmenorrhea, and migraine.

NOVEL COMPOUNDS WITH ANALGESIC EFFECT

Compounds of general formula (I) are disclosed and claimed in the present application, as well as their pharmaceutically acceptable salts, pharmaceutical compositions comprising the novel compounds and their use in therapy, in particular in the management of pain.

NOVEL COMPOUNDS WITH ANALGESIC EFFECT

Compounds of general formula (I) are disclosed and claimed in the present application, as well as their pharmaceutically acceptable salts, pharmaceutical compositions comprising the novel compounds and their use in therapy, in particular in the management of pain.

Inhibitors of histone deacetylase

BIS(BIARYL) COMPOUNDS AS INHIBITORS OF LEUKOTRIENE BIOSYNTHESIS

Compounds having the Formula I: Ar1Ar2-X-Ar3Ar4 are inhibitors of leukotriene biosynthesis. These compounds are useful as anti-asthmatic, anti-allergic, anti-inflammatory, and cytoprotective agents. They are also useful in treating angina, cerebral spasm, glomerular nephritis, hepatitis, endotoxemia, uveitis, and allograft rejection and in preventing the formation of atherosclerotic plaques.

METHODS, COMPOUNDS, COMPOSITIONS AND VEHICLES FOR DELIVERING 3-AMINO-1-PROPANESULFONIC ACID

The invention relates to methods, compounds, compositions and vehicles for delivering 3-amino-1-propanesulfonic acid (3APS) in a subject, preferably a human subject. The invention encompasses compounds that will yield or generate 3APS, either in vitro or in vivo. Preferred compounds include amino acid prodrugs of 3APS for use, including but not limited to, the prevention and treatment of Alzheimer's disease.

Inhibitors of histone deacetylase

The invention relates to the inhibition of histone deacetylase. The invention provides compounds and methods for inhibiting histone deacetylase enzymatic activity. The invention also provides compositions and methods for treating cell proliferative diseases and conditions.

Verfahren zum spezifischen Hemmen von Histon-Deacetylase-4

Verfahren zum Hemmen der HDAC-4-Aktivität in einer Zelle, aufweisend das Kontaktieren der Zelle mit einem Antisense-Oligonucleotid komplementär zu einem RNA-Bereich, der einen Teil von HDAC-4 kodiert, wodurch HDAC-4-Aktivität gehemmt wird.

Bisarylcarbinol cinnamic acids as inhibitors of leukotriene biosynthesis

Methods and compositions for treating amyloid-related diseases

METHODS AND COMPOSITIONS FOR TREATING AMYLOID-RELATED DISEASES

The present application describes methods, compounds, pharmaceutical compositions and kits for treating or preventing amyloid-related diseases. For instance, the application relates to compounds and compositions for inhibiting amyloid formation and/or deposition, for treating or preventing amyloid-related diseases or amyloidosis, or for inhibiting amyloid-induced inflammation or neurotoxicity. The application also relates to methods for production of the compounds described, and their use as pharmaceuticals.

METHODS, COMPOUNDS, COMPOSITIONS AND VEHICLES FOR DELIVERING 3-AMINO-1-PROPANESULFONIC ACID

... ²²²The invention relates to methods, compounds, compositions and vehicles for ²delivering 3-amino-1-propanesulfonic acid (3APS) in a subject, preferably a ²human subject. ²The invention encompasses compounds that will yield or generate 3APS, either ²in vitro or ²in vivo. Preferred compounds include amino acid prodrugs of 3APS for use, ²including but not ²limited to, the prevention and treatment of Alzheimer's disease.² ...

Methods, compounds, compositions and vehicles for delivering 3-amino-1-propanesulfonic acid

The invention relates to methods, compounds, compositions and vehicles for delivering 3-amino-1 -propanesulfonic acid (3APS) in a subject, preferably a human subject. The invention encompasses compounds that yield or generate 3APS, either in vitro or in vivo. Preferred compounds include amino acid prodrugs of 3APS for use, including but not limited to, the prevention and treatment of Alzheimer's disease.

BISARYLCARBINOL ZIMTSÄURE-DERIVATE ZUR HEMMUNG LEUKOTRIENER BIOSYNTHESE

Methods for specifically inhibiting histone deacetylase-4

This invention relates to the inhibition of histone deacetylase (HDAC) expression and enzymatic activity. The invention provides methods and reagents for inhibiting HDAC-4 and HDAC-1 by inhibiting expression at the nucleic acid level or inhibiting enzymatic activity at the protein level. Specific inhibitors are antisense oligonucleotides against HDAC-4 and HDAC-1 and trichostatin analoques.

Bisarylcarbinol derivatives as inhibitors of leukotriene biosynthesis

METHODS, COMPOUNDS, COMPOSITIONS AND VEHICLES FOR DELIVERING3-AMINO-1-PROPANESULFONIC ACID

The invention relates to methods, compounds, compositions and vehicles for delivering 3-amino-1 -propanesulfonic acid (3APS) in a subject, preferably a human subject. The invention encompasses compounds that will yield or generate 3APS, either in vitro or in vivo. Preferred compounds include amino acid prodrugs of 3APS for use, including but not limited to, the prevention and treatment of Alzheimer's disease.

METHODS, COMPOUNDS, COMPOSITIONS AND VEHICLES FOR DELIVERING 3-AMINO-1-PROPANESULFONIC ACID

The invention relates to methods, compounds, compositions and vehicles for delivering 3-amino-1 -propanesulfonic acid (3APS) in a subject, preferably a human subject. The invention encompasses compounds that will yield or generate 3APS, either in vitro or in vivo. Preferred compounds include amino acid prodrugs of 3APS for use, including but not limited to, the prevention and treatment of Alzheimer's disease. © KIPO & WIPO 2009 ...

Bisarylcarbinol derivatives as inhibitors of leukotriene biosynthesis

INHIBITORS OF HISTONE DEACETYLASE

The invention relates to the inhibition of histone deacetylase. The invention provides compounds and methods for inhibiting histone deacetylase enzymatic activity. The invention also provides compositions and methods for treating cell proliferative diseases and conditions. © KIPO & WIPO 2007 ...

SULFONAMIDOMETHYL PHOSPHONATE INHIBITORS OF β-LACTAMASE

The intention relates to bacterial antibiotic resistance and, in particular, to compositions and methods for overcoming bacterial antibiotic resistance. The invention provides novel β-lactamase inhibitors, which are structurally unrelated to the natural product and semi-synthetic β-lactamase inhibitors presently available, and which do not require a β-lactam pharmacophore. The invention also provides pharmaceutical compositions and methods for inhibiting bacterial growth. © KIPO & WIPO 2007 ...

METHODS, COMPOUNDS, COMPOSITIONS AND VEHICLES FOR DELIVERING 3-AMINO-1-PROPANESULFONIC ACID

The invention relates to methods, compounds, compositions and vehicles for delivering 3-amino-1-propanesulfonic acid (3APS) in a subject, preferably a human subject. The invention encompasses compound that will yield or generate 3APS, either in vitro or in vivo. Preferred compounds include amino acid prodrugs of 3APS for use, including but not limited to the prevention and treatment of Alzheimer's disease 112-. (canceled)14. The compound of claim 13 , wherein aais valine and aais absent.15. A pharmaceutical composition comprising the compound or pharmaceutically acceptable salt of and a pharmaceutically acceptable carrier.17. A pharmaceutical composition comprising the compound of and a pharmaceutically acceptable carrier.18. The pharmaceutical composition of in a form suitable for oral administration.19. The pharmaceutical composition of claim 18 , which is in the form of a hard shell gelatin capsule claim 18 , soft shell gelatin capsule claim 18 , cachet claim 18 , pill claim 18 , tablet claim 18 , lozenge claim 18 , powder claim 18 , granule claim 18 , pellet claim 18 , dragee claim 18 , each of which is optionally enteric coated; a solution; an aqueous liquid suspension; a non-aqueous liquid suspension; an oil-in-water liquid emulsion; a water-in-oil liquid emulsion; an elixir; a syrup; or a pastille.20. The pharmaceutical composition of claim 19 , which is in the form of a hard shell gelatin capsule claim 19 , soft shell gelatin capsule claim 19 , or an enterically coated capsule. This application is a continuation of U.S. patent application Ser. No. 15/293,965, filed Oct. 14, 2016, now allowed, which is a continuation of U.S. patent application Ser. No. 14/246,894, filed Apr. 7, 2014, now U.S. Pat. No. 9,499,480, which is a continuation of U.S. patent application Ser. No. 11/871,639, filed Oct. 12, 2007, now U.S. Pat. No. 8,748,656, which claims priority to U.S. Provisional Patent Application No. 60/851,039, filed Oct. 12, 2006, and U.S. Provisional Patent ...

Methods for specifically inhibiting histone deacetylase-7 and 8

Inhibitors of histone deacetylase

Methods, Compounds, Compositions And Vehicles For Delivering 3-Amino-1-Propanesulfonic Acid

Methods, compounds, compositions and vehicles for delivering 3-amino-1-propanesulfonic acid

The invention relates to methods, compounds, compositions and vehicles for delivering 3-amino-1 -propanesulfonic acid (3APS) in a subject, preferably a human subject. The invention encompasses compounds that will yield or generate 3APS, either or . Preferred compounds include amino acid prodrugs of 3APS for use, including but not limited to, the prevention and treatment of Alzheimer's disease.

Bisarylcarbinol cinnamic acids as inhibitors of leukotriene biosynthesis

Inhibitors of histone deacetylase

Inhibitors of histone deacetylase

Phosphonated fluoroquinolones, antibacterial analogs thereof, and methods for the prevention and treatment of bone and joint infections

Aryl thiopyranoÝ2,3,4-c,d¨indoles as inhibitors of leukotriene biosynthesis

INHIBITORS OF HISTONE DEACETYLASE

Novel compounds with analgesic effect

METHODS, COMPOUNDS, COMPOSITIONS AND VEHICLES FOR DELIVERING 3-AMINO-1-PROPANESULFONIC ACID

The invention relates to methods, compounds, compositions and vehicles for delivering 3-amino-1-propanesulfonic acid (3APS) in a subject, preferably a human subject. The invention encompasses compounds that will yield or generate 3APS, either in vitro or in vivo. Preferred compounds include amino acid prodrugs of 3APS for use, including but not limited to, the prevention and treatment of Alzheimer's disease.

METHODS FOR SPECIFICALLY INHIBITING HISTONE DEACETYLASE-7 AND 8

Methods, compounds, compositions and vehicles for delivering 3-amino-1-propanesulfonic acid

The invention relates to methods, compounds, compositions and vehicles for delivering 3-amino-1-propanesulfonic acid (3APS) in a subject, preferably a human subject. The invention encompasses compound that will yield or generate 3APS, either in vitro or in vivo. Preferred compounds include amino acid prodrugs of 3APS for use, including but not limited to the prevention and treatment of Alzheimer's disease.

METHODS AND COMPOSITIONS FOR TREATING AMYLOID-RELATED DISEASES

Methods, compounds, pharmaceutical compositions and kits are described for treating or preventing amyloid-related disease. 23-. (canceled)4. The compound of claim 1 , wherein v is 1.5. The compound of claim 1 , wherein M is a covalent bond or a C-Calkyl.612-. (canceled)13. The compound of claim 1 , wherein B is —CH(M-W)—CH—CH—. —CH—CH(M-W)—CH— claim 1 , or —(CH)—CH—CH(M-W)—.1416-. (canceled)1861-. (canceled)62. A compound of Table 3A or Table 3B claim 1 , or a pharmaceutically acceptable salt claim 1 , ester claim 1 , or prodrug thereof.63. (canceled)64. A method of treating or preventing an amyloid-related disease in a subject comprising administering to a subject in need thereof a compound of claim 1 , or a pharmaceutically acceptable salt thereof claim 1 , in an amount effective to treat or prevent an amyloid related disease.65. The method according to claim 64 , wherein said amyloid-related disease is Alzheimer's disease claim 64 , cerebral amyloid angiopathy claim 64 , inclusion body myositis claim 64 , macular degeneration claim 64 , MCI claim 64 , or Down's syndrome.66. (canceled)67. The method according to claim 64 , wherein said amyloid-related disease is diabetes claim 64 , AA amyloidosis claim 64 , AL amyloidosis claim 64 , ATTR-related amyloidosis claim 64 , or hemodialysis related amyloidosis (βM).6870-. (canceled)71. A method for treating or preventing an amyloid-related disease in a subject in need thereof claim 17 , comprising administering to said subject a therapeutic compound of claim 17 , or a pharmaceutically acceptable salt thereof claim 17 , in an amount effective to treat or prevent an amyloid related disease.72. A method for treating or preventing an amyloid-related disease in a subject in need thereof claim 62 , comprising administering to said subject a therapeutic compound of claim 62 , or pharmaceutically acceptable salts thereof claim 62 , in an amount effective to treat or prevent an amyloid related disease.73119-. (canceled)120. The ...

Inhibitors of histone deacetylase

Sulfonamidomethyl phosphonate inhibitors of beta-lactamase

Inhibitors of histone deacetylase

Inhibitors of histone deacetylase

VERBINDUNGEN MIT ANALGETISCHER WIRKUNG

Inhibitors of histone deacetylase

The invention relates to the inhibition of histone deactylase. The invention provides compounds and methods for inhibiting histone deacetylase enzymatic activity. The invention also provides compositions and methods for treating cell proliferative diseases and conditions.

Methods, compounds, compositions and vehicles for delivering 3-amino-1-propanesulfonic acid

The invention relates to methods, compounds, compositions and vehicles for delivering 3-amino-1-propanesulfonic acid (3APS) in a subject, preferably a human subject. The invention encompasses compound that will yield or generate 3APS, either in vitro or in vivo. Preferred compounds include amino acid prodrugs of 3APS for use, including but not limited to the prevention and treatment of Alzheimer's disease.

Sulfonamidomethylphosphonat-BETA-LACTAMASE-Inhibitoren

Methods, compounds, compositions and vehicles for delivering 3-amino-1-propanesulfonic acid

The invention relates to methods, compounds, compositions and vehicles for delivering 3-amino-1-propanesulfonic acid (3APS) in a subject, preferably a human subject. The invention encompasses compounds that will yield or generate 3APS, either in vitro or in vivo. Preferred compounds include amino acid prodrugs of 3APS for use, including but not limited to, the prevention and treatment of Alzheimer's disease.

Sulfonamidomethyl phosphonate inhibitors of beta-lactamase

The intention relates to bacterial antibiotic resistance and, in particular, to compositions and methods for overcoming bacterial antibiotic resistance. The invention provides novel beta-lactamase inhibitors, which are structurally unrelated to the natural product and semi-synthetic beta-lactamase inhibitors presently available, and which do not require a beta-lactam pharmacophore. The invention also provides pharmaceutical compositions and methods for inhibiting bacterial growth.

Compounds useful in pain management

Compounds of general formula I are disclosed and claimed in the present application, as well as their pharmaceutically acceptable salts, pharmaceutical compositions comprising the novel compounds and their use in therapy, in particular in the management of pain. Intermediates to the compounds of the formula I are also claimed.

INHIBITORS OF HISTONE DEACETYLASE

The invention relates to the inhibition of histone deacetylase. The invention provides compounds and methods for inhibiting histone deacetylase enzymatic activity. The invention also provides compositions and methods for treating cell proliferative diseases and conditions. © KIPO & WIPO 2007 ...

Method and compositions for treating amyloid-related diseases

Methods, compounds, pharmaceutical compositions and kits are described for treating or preventing amyloid-related disease.

INHIBITORS OF HISTONE DEACETYLASE

The invention relates to the inhibition of histone deacetylase. The invention provides compounds and methods for inhibiting histone deacetylase enzymatic activity. The invention also provides compositions and methods for treating cell proliferative diseases and conditions. © KIPO & WIPO 2009 ...

METHOD AND COMPOSITIONS FOR TREATING AMYLOID-RELATED DISEASES

Methods, compounds, pharmaceutical compositions and kits are described for treating or preventing amyloid-related disease. 23.-. (canceled)4. The compound of claim 1 , wherein v is 1.5. The compound of claim 1 , wherein M is a covalent bond or a C-Calkyl.612.-. (canceled)13. The compound of claim 1 , wherein B is —CH(M-W)—CH—CH— claim 1 , —CH—CH(M-W)—CH— claim 1 , or —(CH)—CH—CH(M-W)—.1416.-. (canceled)1861.-. (canceled)62. A compound of Table 3A or Table 3B claim 1 , or a pharmaceutically acceptable salt claim 1 , ester claim 1 , or prodrug thereof.63. (canceled)64. A method of treating or preventing an amyloid-related disease in a subject comprising administering to a subject in need thereof a compound of claim 1 , or a pharmaceutically acceptable salt thereof claim 1 , in an amount effective to treat or prevent an amyloid related disease.65. The method according to claim 64 , wherein said amyloid-related disease is Alzheimer's disease claim 64 , cerebral amyloid angiopathy claim 64 , inclusion body myositis claim 64 , macular degeneration claim 64 , MCI claim 64 , or Down's syndrome.67. (canceled)68. The method according to claim 64 , wherein said amyloid-related disease is diabetes claim 64 , AA amyloidosis claim 64 , AL amyloidosis claim 64 , ATTR-related amyloidosis claim 64 , or hemodialysis related amyloidosis (βM).6971.-. (canceled)72. A method for treating or preventing an amyloid-related disease in a subject in need thereof claim 17 , comprising administering to said subject a therapeutic compound of claim 17 , or a pharmaceutically acceptable salt thereof claim 17 , in an amount effective to treat or prevent an amyloid related disease.73. A method for treating or preventing an amyloid-related disease in a subject in need thereof claim 62 , comprising administering to said subject a therapeutic compound of claim 62 , or pharmaceutically acceptable salts thereof claim 62 , in an amount effective to treat or prevent an amyloid related disease.74120.-. ( ...

Inhibitors of histone deacetylase

The invention relates to the inhibition of histone deacetylase. The invention provides compounds and methods for inhibiting histone deacetylase enzymatic activity. The invention also provides compositions and methods for treating cell proliferative diseases and conditions.

Harnstoffderivate zur Schmerzbekämpfung

NOVEL COMPOUNDS WITH ANALGESIC EFFECT

Compounds of general formula (I) are disclosed and claimed in the present application, as well as their pharmaceutically acceptable salts, pharmaceutical compositions comprising the novel compounds and their use in therapy, in particular in the management of pain. © KIPO & WIPO 2007 ...

Inhibitors of histone deacetylase

The invention relates to the inhibition of histone deactylase. The invention provides compounds and methods for inhibiting histone deacetylase enzymatic activity. The invention also provides compositions and methods for treating cell proliferative diseases and conditions.

METHODS, COMPOUNDS, COMPOSITIONS AND VEHICLES FOR DELIVERING 3-AMINO-1-PROPANESULFONIC ACID

The invention relates to methods, compounds, compositions and vehicles for delivering 3-amino-1-propanesulfonic acid (3APS) in a subject, preferably a human subject. The invention encompasses compound that will yield or generate 3APS, either in vitro or in vivo. Preferred compounds include amino acid prodrugs of 3APS for use, including but not limited to the prevention and treatment of Alzheimer's disease 5. A method for treating Alzheimer's disease claim 1 , mild cognitive impairment claim 1 , Down's syndrome claim 1 , Hereditary Cerebral Hemorrhage with Amyloidosis of the Dutch-Type claim 1 , cerebral amyloid angiopathy claim 1 , a degenerative dementia claim 1 , a dementia of mixed vascular and degenerative origin claim 1 , dementia associated with Parkinson's disease claim 1 , dementia associated with progressive supranuclear palsy claim 1 , dementia associated with cortical basal degeneration claim 1 , or diffuse Lewy body type of Alzheimer's disease claim 1 , comprising administering a therapeutically effective amount of a compound of to a human subject in need thereof.6. The method of claim 5 , which is for treating Alzheimer's disease claim 5 , mild cognitive impairment claim 5 , cerebral amyloid angiopathy claim 5 , or degenerative dementia.7. The method of claim 6 , which is for treating Alzheimer's disease.8. The method of wherein the compound is administered intratracheally claim 5 , intranasally claim 5 , ontologically claim 5 , rectally claim 5 , vaginally claim 5 , or orally.9. A pharmaceutical composition comprising a compound of together with a pharmaceutically acceptable carrier.10. The pharmaceutical composition of which is suitable for oral administration.11. The pharmaceutical composition of claim 9 , which is in the form of a hard shell gelatin capsule claim 9 , soft shell gelatin capsule claim 9 , cachet claim 9 , pill claim 9 , tablet claim 9 , lozenge claim 9 , powder claim 9 , granule claim 9 , pellet claim 9 , dragee claim 9 , which is ...

METHODS, COMPOUNDS, COMPOSITIONS AND VEHICLES FOR DELIVERING 3-AMINO-1-PROPANESULFONIC ACID

The invention relates to methods, compounds, compositions and vehicles for delivering 3-amino-1-propanesulfonic acid (3APS) in a subject, preferably a human subject. The invention encompasses compound that will yield or generate 3APS, either in vitro or in vivo. Preferred compounds include amino acid prodrugs of 3APS for use, including but not limited to the prevention and treatment of Alzheimer's disease 5. A method for treating Alzheimer's disease claim 1 , mild cognitive impairment claim 1 , Down's syndrome claim 1 , Hereditary Cerebral Hemorrhage with Amyloidosis of the Dutch-Type claim 1 , cerebral amyloid angiopathy claim 1 , a degenerative dementia claim 1 , a dementia of mixed vascular and degenerative origin claim 1 , dementia associated with Parkinson's disease claim 1 , dementia associated with progressive supranuclear palsy claim 1 , dementia associated with cortical basal degeneration claim 1 , or diffuse Lewy body type of Alzheimer's disease claim 1 , comprising administering a therapeutically effective amount of a compound of to a human subject in need thereof.6. The method of claim 5 , which is for treating Alzheimer's disease claim 5 , mild cognitive impairment claim 5 , cerebral amyloid angiopathy claim 5 , or degenerative dementia.7. The method of claim 6 , which is for treating Alzheimer's disease.8. The method of wherein the compound is administered intratracheally claim 5 , intranasally claim 5 , ontologically claim 5 , rectally claim 5 , vaginally claim 5 , or orally.9. A pharmaceutical composition comprising a compound of together with a pharmaceutically acceptable carrier.10. The pharmaceutical composition of which is suitable for oral administration.11. The pharmaceutical composition of claim 9 , which is in the form of a hard shell gelatin capsule claim 9 , soft shell gelatin capsule claim 9 , cachet claim 9 , pill claim 9 , tablet claim 9 , lozenge claim 9 , powder claim 9 , granule claim 9 , pellet claim 9 , dragee claim 9 , which is ...

METHODS, COMPOUNDS, COMPOSITIONS AND VEHICLES FOR DELIVERING 3-AMINO-1-PROPANESULFONIC ACID

The invention relates to methods, compounds, compositions and vehicles for delivering 3-amino-1-propanesulfonic acid (3APS) in a subject, preferably a human subject. The invention encompasses compound that will yield or generate 3APS, either in vitro or in vivo. Preferred compounds include amino acid prodrugs of 3APS for use, including but not limited to the prevention and treatment of Alzheimer's disease 5. A method for treating Alzheimer's disease claim 1 , mild cognitive impairment claim 1 , Down's syndrome claim 1 , Hereditary Cerebral Hemorrhage with Amyloidosis of the Dutch-Type claim 1 , cerebral amyloid angiopathy claim 1 , a degenerative dementia claim 1 , a dementia of mixed vascular and degenerative origin claim 1 , dementia associated with Parkinson's disease claim 1 , dementia associated with progressive supranuclear palsy claim 1 , dementia associated with cortical basal degeneration claim 1 , or diffuse Lewy body type of Alzheimer's disease claim 1 , comprising administering a therapeutically effective amount of a compound of to a human subject in need thereof.6. The method of claim 5 , which is for treating Alzheimer's disease claim 5 , mild cognitive impairment claim 5 , cerebral amyloid angiopathy claim 5 , or degenerative dementia.7. The method of claim 6 , which is for treating Alzheimer's disease.8. The method of wherein the compound is administered intratracheally claim 5 , intranasally claim 5 , ontologically claim 5 , rectally claim 5 , vaginally claim 5 , or orally.9. A pharmaceutical composition comprising a compound of together with a pharmaceutically acceptable carrier.10. The pharmaceutical composition of which is suitable for oral administration.11. The pharmaceutical composition of claim 9 , which is in the form of a hard shell gelatin capsule claim 9 , soft shell gelatin capsule claim 9 , cachet claim 9 , pill claim 9 , tablet claim 9 , lozenge claim 9 , powder claim 9 , granule claim 9 , pellet claim 9 , dragee claim 9 , which is ...

Inhibitors of histone deacetylase

The invention relates to the inhibition of histone deacetylase. The invention provides compounds and methods for inhibiting histone deacetylase enzymatic activity. The invention also provides compositions and methods for treating cell proliferative diseases and conditions.

Inhibitors of histone deacetylase

The invention provides compoods and methods for treating cell proliferative- diseases. The invention provides new inhibitors of histone deacetylase enzymatic activity, compositions of the compounds comprising the inhibitors and a pharmaceutically acceptable carrier, excipient, or diluent, and methods of using the compounds to inhibit cellular proliferation in vitro and therapeutically.

Inhibitors of dna methyltransferase

The invention relates to the inhibition of DNA methyltransferase isoforms DNMT1 and DNMT3b2. The invention provides compounds and methods for inhibiting DNMT1 and DNMT3b2.

Inhibitors of histone deacetylase

The invention relates to the inhibition of histone deacetylase. The invention provides compounds and methods for inhibiting histone deacetylase enzymatic activity. The invention also provides compositions and methods for treating cell proliferative diseases and conditions.

Inhibitors of histone deacetylase

The invention relates to the inhibition of histone deacetylase. The invention provides compounds e.g. (1) and methods for inhibiting deacetylase enzymatic activity. The invention also provides compositions and methods for treating cell proliferative diseases and conditions. (formula 1). All definitions are as the application.

Inhibitors of histone deacetylase

The invention provides compoods and methods for treating cell proliferative- diseases. The invention provides new inhibitors of histone deacetylase enzymatic activity, compositions of the compounds comprising the inhibitors and a pharmaceutically acceptable carrier, excipient, or diluent, and methods of using the compounds to inhibit cellular proliferation in vitro and therapeutically.

Inhibitors of histone deacetylase

The invention relates to a series of compounds useful for inhibiting histone deacetylase (HDAC) enzymatic activity. The invention also provides a method for inhibiting histone descetylase in a cell using said compounds as well as a method for treating cell proliferative diseases and conditions using said HDAC inhibitors. Further, the invention provides pharmaceutical compositions comprising the HDAC inhibiting compounds and a pharmaceutically acceptable carrier.

Inhibitors of histone deacetylase

The invention relates to the inhibition of histone deacetylase. The invention provides compounds and methods for inhibiting histone deacetylase enzymatic activity. The invention also provides compositions and methods for treating cell proliferative diseases and conditions.

Inhibitors of histone deacetylase

The invention relates to the inhibition of histone deactylase. The invention provides compounds and methods for inhibiting histone deacetylase enzymatic activity. The invention also provides compositions and methods for treating cell proliferative diseases and conditions.

Inhibitors of histone deacetylase

The invention relates to the inhibition of histone deactylase. The invention provides compounds and methods for inhibiting histone deacetylase enzymatic activity. The invention also provides compositions and methods for treating cell proliferative diseases and conditions.

Inhibitors of histone deacetylase

The invention relates to the inhibition of histone deacetylase. The invention provides compounds and methods for inhibiting histone deacetylase enzymatic activity. The invention also provides compositions and methods for treating cell proliferative diseases and conditions.

Inhibitors of histone deacetylase

The invention provides compoods and methods for treating cell proliferative-diseases. The invention provides new inhibitors of histone deacetylase enzymatic activity, compositions of the compounds comprising the inhibitors and a pharmaceutically acceptable carrier, excipient, or diluent, and methods of using the compounds to inhibit cellular proliferation in vitro and therapeutically.

Inhibitors of histone deacetylase

The invention relates to the inhibition of histone deacetylase. The invention provides compounds and methods for inhibiting histone deacetylase enzymatic activity. The invention also provides compositions and methods for treating cell proliferative diseases and conditions.

Methods for specifically inhibiting histone deacetylase-4

This invention relates to the inhibition of histone deacetylase (HDAC) expression and enzymatic activity. The invention provides methods and reagen ts for inhibiting HDAC-4 and HDAC-1 by inhibiting expression at the nucleic aci d level or inhibiting enzymatic activity at the protein level.

Inhibitors of histone deacetylase

The invention relates to the inhibition of histone deacetylase. The inventio n provides compounds e.g. (1) and methods for inhibiting deacetylase enzymatic activity. The invention also provides compositions and methods for treating cell proliferative diseases and conditions. (formula 1). All definitions are as the application.

Inhibitors of histone deacetylase

The invention relates to the inhibition of histone deacetylase. The invention provides compounds e.g. (1) and methods for inhibiting deacetylase enzymatic activity. The invention also provides compositions and methods for treating cell proliferative diseases and conditions. (formula 1). All definitions are as the application.

Inhibitors of histone deacetylase

Methods for specifically inhibiting histone deacetylase-7 and 8

This invention relates to the inhibition of histone deacetylase (HDAC) expression and enzymatic activity. The invention provides methods and reagen ts for inhibiting HDAC-7 and HDAC-8 by inhibiting expression at the nucleic aci d level or inhibiting enzymatic activity at the protein level.

Novel compounds exhibiting analgesic properties

Compounds of general formula (I) are disclosed and claimed in the present application, as well as their pharmaceutically acceptable salts, pharmaceutical compositions comprising the novel compounds and their use in therapy, in particular in the management of pain.

System for learning English language by French student, has sensor associated with student to emit signal representative of cerebral activity of student and analysis unit for representative to determine if student is proper in desired state

The system (1) has a relaxation assistance device (2) designed for subjecting a student to light signals and/or sound to bring the student in a mild or deep relaxation state. A sound emitting device (3) allows the student to hear a text in a language to be learned. A control device (7) controls level of relaxation of the student and includes a sensor (8) to be associated with the student to emit an analog or digital signal representative of cerebral activity of the student and an analysis unit for the signal representative to determine if the student is proper in the state. An independent claim is also included for a method for training a language to a student.

Methods, compounds, compositions and vehicles for delivering 3-amino-1-propanesulfonic acid

The invention relates to methods, compounds, compositions and vehicles for delivering 3-amino-1 -propanesulfonic acid (3APS) in a subject, preferably a human subject. The invention encompasses compounds that will yield or generate 3APS, either in vitro or in vivo. Preferred compounds include amino acid prodrugs of 3APS for use, including but not limited to, the prevention and treatment of Alzheimer's disease.

Methods, compounds, compositions and vehicles for delivering 3-amino-1-propanesulfonic acid

Novel compounds exhibiting analgetic activity

PRESENTATION DEVICE

Methods and compositions for treating amyloid-related diseases

Compounds of formulae (VIII), (IX), (X), (XI), (XII) (XIII), (XIV) and (XV), in which the variables are as defined in the claims are described, as well as methods, pharmaceutical compositions and kits for treating or preventing amyloid-related disease.

Methods, compounds, compositions and vehicles for delivering 3-amino-1-propanesulfonic acid

Novel compounds

Compounds of general formula (I) are disclosed and claimed in the present application, as well as their pharmaceutically acceptable salts, pharmaceutical compositions comprising the novel compounds and their use in therapy, in particular in the management of pain.

Methods, compounds, compositions and vehicles for delivering 3-amino-1-propanesulfonic acid

The invention relates to methods, compounds, compositions and vehicles for delivering 3-amino-1-propanesulfonic acid (3APS) in a subject, preferably a human subject. The invention encompasses compound that will yield or generate 3APS, either in vitro or in vivo. Preferred compounds include amino acid prodrugs of 3APS for use, including but not limited to the prevention and treatment of Alzheimer's disease

Inhibitors of histone deacetylase

The invention relates to a series of compounds useful for inhibiting histone deacetylase (HDAC) enzymatic activity. The invention also provides a method for inhibiting histone descetylase in a cell using said compounds as well as a method for treating cell proliferative diseases and conditions using said HDAC inhibitors. Further, the invention provides pharmaceutical compositions comprising the HDAC inhibiting compounds and a pharmaceutically acceptable carrier. (see above formula)

Methods, compounds, compositions and vehicles for delivering 3-amino-1-propanesulfonic acid

Un compuesto de Fórmula IV, o una de sus sales farmacéuticamente aceptables o solvatos: en donde: aa1 es un residuo de aminoácido natural o no natural; aa2 es un residuo de aminoácido natural o no natural, o está ausente; en donde dichos aa1 y aa2 son cada uno independientemente residuos de aminoácido de Fórmula VI: en donde: R1 se selecciona del grupo que consiste en un grupo sustituido o no sustituido seleccionado de alquilo C1-C12, alquenilo C2-C12, alquinilo C2-C12, cicloalquilo C3-C15; R2 es hidrógeno R3 es hidrógeno; o R3 es un enlace entre dos residuos de aminoácido, cuando están presentes dos residuos de aminoácido; R4 se selecciona del grupo que consiste en H y un grupo sustituido o no sustituido seleccionado de alquilo C1-C6, alquenilo C2-C6, alquinilo C2-C6; y n es 1, 2 o 3; en donde el término sustituido cuando está asociado con cualquiera de los grupos precedentes se refiere a un grupo sustituido en una o más posiciones con sustituyentes seleccionados de amino simple, mono y dialquilamino, mono y diarilamino, y alquilarilamino, acilamino incluyendo carbamoílo, y ureido, aminocarbonilo, mono y dialquilaminocarbonilo, ciano, azido, halógeno, hidroxilo, nitro, trifluorometilo, alquilo C1-C6, alquenilo C2-C6, alquinilo C2-C6, cicloalquilo, heterocicloalquilo, arilo, heteroarilo, alcoxi C1-C6, ariloxi, benciloxi, bencilo, guanidino, imino y formilo; con la condición de que cuando R2 sea H y R3 sea H o un enlace, entonces R1 no sea un grupo -CH2fenilo. A compound of Formula IV, or a pharmaceutically acceptable salt or solvate thereof: wherein: aa1 is a natural or non-natural amino acid residue; aa2 is a natural or unnatural amino acid residue, or is absent; wherein said aa1 and aa2 are each independently amino acid residues of Formula VI: wherein: R1 is selected from the group consisting of a substituted or unsubstituted group selected from C1-C12 alkyl, C2-C12 alkenyl, C2-C12 alkynyl , C3-C15 cycloalkyl; R2 is hydrogen R3 is hydrogen; or R3 is a link between ...

Inhibitors of histone deacetylase

The invention relates to the inhibition of histone deacetylase. The invention provides compounds and methods for inhibiting histone deacetylase enzymatic activity. The invention also provides compositions and methods for treating cell proliferative diseases and conditions.

Compounds with analgesic properties

Inhibitors of histone deacetylase

The invention relates to the inhibition of histone deacetylase. The invention provides compounds for inhibiting histone deacetylase enzymatic activity. The compounds for inhibiting histone deacetylase enzymatic activity can be represented by the formulas Cy-L1-Ar Y1-C(O)-NH-Z Cy-L2 Ar-Y2-C(O)NH-Z Cy-L3 Ar-Y3-C(O)NH-Z, wherein Cy, L1, L2, L3, Ar, Y1, Y2, Y3 and Z are as defined in the application.

Sulfonamidomethyl phosphonate inhibitors of .beta.-lactamase

The intention relates to bacterial antibiotic resistance and, in particular, to compositions and methods for overcoming bacterial antibiotic resistance. The invention provides novel .beta.-lactamase inhibitors, which are structurally unrelated to the natural product and semi-synthetic .beta.-lactamase inhibitors presently available, and which do not require a .beta.-lactam pharmacophore. The invention also provides pharmaceutical compositions and methods for inhibiting bacterial growth.

UREA DERIVATIVES FOR THE TREATMENT OF PAIN.

Un compuesto de fórmula I en la que: m = n = 1 R1 se selecciona de (i) un alquilo C1-C6 lineal o ramificado; e (ii)hidrógeno; R2 se selecciona de (i) metilo; o (ii)fenilo opcionalmente sustituido con 1 ó 2 sustituyentes Y, en los que Y es como se define más abajo; R3 se selecciona de (i) -CH2-fenilo opcionalmente sustituido con 1 ó 2 sustituyentes Y, en los que Y es como se define más abajo; (ii)-CH2-ciclohexilo; R4 se selecciona de (i) hidrógeno; o (ii)metilo; R5 se selecciona de (i) hidrógeno; (ii)metilo; o (iii) o R4 y R5 forman juntos un anillo heterocíclico, opcionalmente sustituido con 1 ó 2 sustituyentes Y, en los que Y se selecciona individual e independientemente de cualquiera de hidrógeno, CH3, -(CH2)p1CF3, halógeno, alcoxi C1-C3, hidroxi, -NO2, -OCF3, -CONRaRb, -COORa, - CORa, -(CH2)p2NRaRb, -(CH2)p3CH3, -(CH2)p5SO2Ra, (alquilcicloalquilo) C4-C8 en el que alquilo tiene C1-C2 y el cicloalquilo es cicloalquilo C3-C6; y en los que Ra y Rb se seleccionan individual e independientemente de hidrógeno, un alquilo C1-C6 ramificado o lineal, alquenilo C1-C6, cicloalquilo C3-C8, y en los que p1, p2, p3, p4, p5 y p6 es cada uno e independientemente 0, 1 ó 2, así como sus sales farmacéuticamente aceptables. A compound of formula I in which: m = n = 1 R1 is selected from (i) a linear or branched C1-C6 alkyl; and (ii) hydrogen; R2 is selected from (i) methyl; or (ii) phenyl optionally substituted with 1 or 2 substituents Y, in which Y is as defined below; R3 is selected from (i) -CH2-phenyl optionally substituted with 1 or 2 substituents Y, in which Y is as defined below; (ii) -CH2-cyclohexyl; R4 is selected from (i) hydrogen; or (ii) methyl; R5 is selected from (i) hydrogen; (ii) methyl; or (iii) or R4 and R5 together form a heterocyclic ring, optionally substituted with 1 or 2 Y substituents, in which Y is selected individually and independently from any of hydrogen, CH3, - (CH2) p1CF3, halogen, C1- alkoxy C3, hydroxy, -NO2, -OCF3, -CONRaRb, -COORa, - CORa, - (CH2) ...

Methods and compositions for treating amyloid-related diseases

Compounds of formulae (VIII), (IX), (X), (XI), (XII) (XIII), (XIV) and (XV), in which the variables are as defined in the claims are described, as well as methods, pharmaceutical compositions and kits for treating or preventing amyloid-related disease.

Methods, compounds, compositions and vehicles for delivering 3-amino-1-propanesulfonic acid

The invention relates to methods, compounds, compositions and vehicles for delivering 3-amino-1-propanesulfonic acid (3APS) in a subject, preferably a human subject. The invention encompasses compound that will yield or generate 3APS, either in vitro or in vivo. Preferred compounds include amino acid prodrugs of 3APS for use, including but not limited to the prevention and treatment of Alzheimer's disease.

Dibenzoheterocyclic hydroxamic acids and hydroxy ureas as inhibitors of 5-lipoxygenase

Compounds having the formula I: ##STR1## are inhibitors of the 5-lipoxygenase enzyme. These compounds are useful as anti-asthmatic, anti-allergic, anti-inflammatory, and cytoprotective agents. They are also useful in treating diarrhea, hypertension, angina, platelet aggregation, cerebral spasm, premature labor, spontaneous abortion, dysmenorrhea, and migraine.

Phosphonated fluoroquinolones, antibacterial analogs thereof, and methods for the prevention and treatment of bone and joint infections

The present invention relates to phosphonated fluoroquinolones such as moxifloxacm, gatifloxacm and ciprofloxacin, antibacterial analogs thereof, and methods of using such compounds The disclosed compounds represent prodrugs of fluoroquinolones wherein a phosphonated group is tethered to a fluoroquinolone antibiotic via a cleavable linker These compounds are useful as antibiotics for prevention and/or treatment of bone and joint infections, especially for the prevention and/or treatment of osteomyelitis

Compounds with analgesic-containing effects of olefin

Harnstoffderivate zur schmerzbekämpfung

Methods, compounds, compositions and vehicles for delivering 3-amino-1-propanesulfonic acid

The invention relates to methods, compounds, compositions and vehicles for delivering 3-amino-1-propanesulfonic acid (3APS) in a subject, preferably a human subject. The invention encompasses compounds that will yield or generate 3APS, either in vitro or in vivo. Preferred compounds include amino acid prodrugs of 3APS for use, including but not limited to, the prevention and treatment of Alzheimer's disease.

Sposoby, związki, kompozycje i nośniki dostarczające kwas 3-amino-1-propanosulfonowy

Postopki, spojine, sestavki in vehikli za dostavljanje 3-amino-1- propansulfonske kisline

Menetelmiä, yhdisteitä, koostumuksia ja vehikkeleitä 3-amino-1-propaanisulfonihapon vapauttamiseksi

Metodai, junginiai, kompozicijos ir transporteriai, skirti 3- amino-1- propansulfonrūgšties pristatymui

Fremgangsmåder, forbindelser, sammensætninger og vehikler til administration af 3-amino-1-propansulfonsyre

Inhibitoren für histone-deacetylase

Inhibitoren der histon-deacetylase

Histondeacetylase-hemmer

Verbindungen mit analgetischer wirkung

Sulfonamidomethyl phosphonat beta-lactamase inhibitoren

Métodos, compuestos, composiciones y vehículos para suministrar ácido 3-amino-1-propanosulfónico

La invención se refiere a métodos, compuestos, composiciones y vehículos para administrar ácido 3-amino-1-propanosulfónico (3APS) en un sujeto, preferiblemente un sujeto humano. La invención abarca compuestos que producirán o generarán 3APS, ya sea in vitro o in vivo. Los compuestos preferidos incluyen profármacos de aminoácidos de 3APS para su uso, incluyendo, entre otros, la prevención y el tratamiento de la enfermedad de Alzheimer. (Traducción automática con Google Translate, sin valor legal)

Heteroarylnaphthalenes as inhibitors of leukotriene biosynthesis

Phosphonated oxazolidinones and uses thereof for the prevention and treatment of bone and joint infections

The invention relates to bisphosphonated derivatives of oxazolidmones represented by formula (I) where A is an oxazolidmone antimicrobial molecule, B is a phosphonated group and L is bond or a linker for covalently coupling B to A These derivatives are useful as antibiotics for the prevention and/or treatment of bone and joint infections, especially osteomyelitis [B- L-]n- A (I)

Novel compounds useful in pain management

Compounds of general formula (I) are disclosed and claimed in the present application, as well as their pharmaceutically acceptable salts, pharmaceutical compositions comprising the novel compounds and their use in therapy, in particular in the management of pain.

Novel compounds with analgesic effect.